Cited 10 times in
Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without caridiovascular event
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 차봉수 | - |
dc.contributor.author | 강은석 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이현철 | - |
dc.date.accessioned | 2015-01-06T17:21:15Z | - |
dc.date.available | 2015-01-06T17:21:15Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1355-008X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99821 | - |
dc.description.abstract | We investigated the efficacy of cilostazol treatment for 2 years on the attenuation of carotid intima-media thickness (IMT) progression in type 2 diabetic patients without cardiovascular disease history, as compared with other antiplatelet agents. We recruited a total of 230 type 2 diabetic patients who had undergone IMT measurement twice within 1.5–2.5 years (mean 2.06 ± 0.32 years) interval. Among these participants, we classified them into three groups according to antiplatelet agent administration at baseline: Group I (n = 66), antiplatelet naïve; Group II (n = 75), other antiplatelet agent administration; and Group III (n = 50), cilostazol administration. We then analyzed the changes in clinical characteristics from baseline to 2 years. The changes in annual mean IMT at 2 years were 0.019 ± 0.045 mm/year, −0.001 ± 0.058 mm/year, and −0.019 ± 0.043 mm/year for Group I, II, and III, respectively (P < 0.001). Mean change in total cholesterol, low-density lipoprotein-cholesterol, and triglyceride compared with baseline decreased the most in Group III even after adjustment for statin use. We also observed that the odds ratio of carotid IMT progression at 2 years was the lowest in patients who were treated with cilostazol even after adjustment for change of metabolic parameters. When we categorized patients according to baseline carotid IMT tertile, the efficacy of cilostazol against carotid IMT progression was significant only when baseline IMT was over 0.662 mm (mean 0.801). Two-year treatment with cilostazol strongly inhibited carotid IMT progression compared to other antiplatelet agents in type 2 diabetic patients. This beneficial effect of cilostazol was significant when baseline IMT was thicker than 0.662 mm (mean 0.801 mm). | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 138~145 | - |
dc.relation.isPartOf | ENDOCRINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Cardiovascular Diseases/prevention & control* | - |
dc.subject.MESH | Carotid Arteries/diagnostic imaging | - |
dc.subject.MESH | Carotid Arteries/drug effects* | - |
dc.subject.MESH | Carotid Intima-Media Thickness* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/complications | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/diagnostic imaging | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/epidemiology | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Longitudinal Studies | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/pharmacology* | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/therapeutic use | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tetrazoles/pharmacology* | - |
dc.subject.MESH | Tetrazoles/therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without caridiovascular event | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Ji Hye Huh | - |
dc.contributor.googleauthor | Hannah Seok | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.contributor.googleauthor | Hyun Chul Lee | - |
dc.contributor.googleauthor | Bong Soo Cha | - |
dc.identifier.doi | 10.1007/s12020-013-0120-y | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03996 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A03301 | - |
dc.relation.journalcode | J00768 | - |
dc.identifier.eissn | 1559-0100 | - |
dc.identifier.pmid | 24381128 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs12020-013-0120-y | - |
dc.subject.keyword | Intima-media thickness (IMT) | - |
dc.subject.keyword | Type 2 diabetes mellitus | - |
dc.subject.keyword | Cilostazol | - |
dc.subject.keyword | Lipid profile | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 47 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 138 | - |
dc.citation.endPage | 145 | - |
dc.identifier.bibliographicCitation | ENDOCRINE, Vol.47(1) : 138-145, 2014 | - |
dc.identifier.rimsid | 49625 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.